41. Recall that article presenting the results from a randomized trial that enrolled HIV sero-discordant couples is several countries. As per the abstract: BACKGROUND Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. METHODS In nine countries, we enrolled 1763 couples in which one partner was HIV-1-positive and the other was HIV-1-negative; 54% of the subjects were from Africa, and 50% of infected partners were men. HIV-1-infected subjects with CD4 counts between 350 and 550 cells per cubic millimeter were randomly assigned in a 1:1 ratio to receive antiretroviral therapy either immediately (early therapy) or after a decline in the CD4 count or the onset of HIV-1-related symptoms (delayed therapy). The primary preven- tion end point was linked HIV-1 transmission in HIV-1-negative partners. The pri- mary clinical end point was the earliest occurrence of pulmonary tuberculosis, severe bacterial infection, a World Health Organization stage 4 event, or death. Additionally, the results from both simple and multiple Cox regression models were summarized in the following table: Table 3. Hazard Ratios for Prognostic Factors for Partner-Linked and Any HIV-1 Transmission and for Clinical and Composite Events.* Linked Any Clinical Composite Variable Transmission Transmission Events Events hazard ratio (95% CI) Univariate analysis Early therapy vs. delayed therapy 0.04 (0.01-0.26) 0.11 (0.04 0.32) 0.60 (0.41-0.90) 0.28 (0.18-0.45) Baseline CD4 count (per 100 CD4 1.27 (1.02-1.59) 1.25 (1.02-1.52) 0.84 (0.70-1.00) 1.06 (0.91-1.24) increment) Baseline viral load (per unit logo 1.96 (1.17-3.27) 1.66 (1.08 2.55) 1.74 (1.32 2.30) 1.51 (1.15-1.97) increment) Male sex vs. female sex 0.69 (0.31-1. 52) 0.88 (0.45-1.71) 1.61 (1.05 2.48) 1.18 (0.78-1.78) Baseline condom use (1006 vs.